» Articles » PMID: 15221864

Immunophenotypic Differentiation Patterns of Normal Hematopoiesis in Human Bone Marrow: Reference Patterns for Age-related Changes and Disease-induced Shifts

Overview
Specialty Cell Biology
Date 2004 Jun 29
PMID 15221864
Citations 105
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The abundance of monoclonal antibodies (mAb) and the routine use of quadruple stainings in flow cytometry allow stepwise analysis of bone marrow (BM) samples that are suspected for abnormal hematopoiesis. A screening phase that precedes lineage-specific classification phases should be sufficient to assess whether the BM has a normal or abnormal composition, as well as to identify the abnormal differentiation lineage.

Methods: For a quick and easy flow cytometric screening of BM samples, we selected six quadruple immunostainings that cover multiple differentiation stages of the B-cell, monocytic, granulocytic, and erythroid lineages: TdT/CD20/CD19/CD10 and CD45/CD34/CD19/CD22 for B cells, CD34/CD117/CD45/CD13.33 for precursor granulocytic and precursor monocytic cells (myelo/monoblasts), CD14/CD33/CD45/CD34 for monocytic cells, CD16/CD13/CD45/CD11b for granulocytic cells, and CD71/CD235a/CD45/CD117 for erythroid cells.

Results: The six quadruple immunostainings reveal specific staining patterns in normal BM, which allow the recognition of various subpopulations of the respective lineages. These staining patterns can be used as a frame of reference for recognition of normal and abnormal BM development. Examples of normal (age-related) variations in these otherwise stable staining patterns are presented together with several abnormal differentiation patterns.

Conclusions: Although alternative immunostainings can be used (e.g., including NK- and T-cell markers), we feel that the selected six stainings represent a comprehensive and easy screening phase for quick identification of shifts in the composition of the studied differentiation lineages, reflecting age-related changes or disease-induced BM abnormalities.

Citing Articles

Prognostic value of myeloid-derived suppressor-like cells in acute myeloid leukemia: insights from immunophenotyping and clinical correlations.

SantAna A, Dias C, Nunes V, Farias M, Alegretti A, Portela P Immunol Res. 2024; 73(1):11.

PMID: 39673675 DOI: 10.1007/s12026-024-09558-6.


Acute Myeloid Leukemia: Diagnosis and Evaluation by Flow Cytometry.

Ally F, Chen X Cancers (Basel). 2024; 16(22).

PMID: 39594810 PMC: 11592599. DOI: 10.3390/cancers16223855.


Long-term lineage commitment in haematopoietic stem cell gene therapy.

Calabria A, Spinozzi G, Cesana D, Buscaroli E, Benedicenti F, Pais G Nature. 2024; 636(8041):162-171.

PMID: 39442556 PMC: 11618100. DOI: 10.1038/s41586-024-08250-x.


Bithionol eliminates acute myeloid leukaemia stem-like cells by suppressing NF-κB signalling and inducing oxidative stress, leading to apoptosis and ferroptosis.

Dias I, Costa R, Rodrigues A, Silva S, Oliveira M, Soares M Cell Death Discov. 2024; 10(1):390.

PMID: 39209810 PMC: 11362533. DOI: 10.1038/s41420-024-02148-3.


Lenalidomide and pomalidomide modulate hematopoietic cell expansion and differentiation in the presence of MSC.

Fujii S, Miura Y Int J Hematol. 2024; 120(3):278-289.

PMID: 38995485 PMC: 11362235. DOI: 10.1007/s12185-024-03815-y.